Growth Drug Received New Pediatric Recommendations
Regulators recommended the drug Sogroya for three additional childhood growth conditions.
Updated on Sept. 22, 2026 in Children’s Health
Live Poll
Should regulatory bodies expand approvals for growth hormone therapies in children?
The European Medicines Agency committee has recommended expanding the use of the drug Sogroya to include idiopathic short stature, children born small for gestational age, and Noonan syndrome. These new indications offer a once-weekly dosing option for children currently undergoing growth hormone therapy.
Why it matters
Expanding these pediatric indications could provide a simplified treatment schedule for families by replacing daily injections with a once-weekly regimen. This recommendation follows a re-examination of an initial opinion issued by the committee in May 2026.
In the phase 3 REAL8 trial, once-weekly somapacitan demonstrated noninferiority to daily growth hormone therapy over 52 weeks of evaluation. The recommendation for these three new indications follows a formal re-examination of an initial regulatory opinion.
The players
European Medicines Agency
The agency responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union.
Committee for Medicinal Products for Human Use
The committee within the European Medicines Agency that assesses applications for marketing authorization for human medicines.
The details
Somapacitan is a recombinant human growth hormone analogue designed to be long-acting. The molecule is engineered with a reversible albumin-binding moiety that attaches to circulating albumin in the blood, which effectively extends the drug's half-life and allows for once-weekly subcutaneous dosing rather than daily administration.
Timeline
March 2021: Sogroya was initially approved for adult growth hormone deficiency.
July 2023: The drug received approval for pediatric growth hormone deficiency.
May 2026: The committee issued its initial opinion regarding the drug.
September 22, 2026: The committee issued a positive opinion for three new pediatric indications.
Late November 2026: Final European Commission marketing authorization is expected.
Health Landscape
This development marks an expansion of long-acting treatment options within the pediatric growth hormone market. It follows the clinical data established by the REAL8 trial, which evaluated the efficacy of shifting from daily to weekly injection protocols.
If you are currently managing growth hormone therapy for a child, discuss these potential treatment options with your endocrinologist to understand if a once-weekly formulation is appropriate. This change specifically affects care for idiopathic short stature, Noonan syndrome, and growth patterns in children born small for gestational age.
The takeaway
The move toward once-weekly growth hormone therapies aims to reduce the burden of daily injections for pediatric patients. Families interested in these developments should track future European Commission authorization updates and consult their specialist about upcoming treatment options.
What happens next
The European Commission is expected to finalize the formal marketing authorization within 67 days of the September 22, 2026, recommendation.
Further reading
Find more clinical context and treatment trends in our Children’s Health section.
Source note: This article includes information reported by Medscape.
Live Poll
Should regulatory bodies expand approvals for growth hormone therapies in children?
